- Radius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021.
- Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to.
- Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Reevaluating Radius Health